Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy

Zhang,Longyang; Guo,Feng; Gao,Xinghua; Wu,Yanlin

doi:10.3892/mmr.2015.3455

Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy

Authors:
- Longyang Zhang
- Feng Guo
- Xinghua Gao
- Yanlin Wu
View Affiliations

Affiliations: Department of Urology, Jinan Central Hospital of Shandong University, Jinan, Shangdong 250013, P.R. China
Published online on: March 9, 2015 https://doi.org/10.3892/mmr.2015.3455
Pages: 1298-1304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Golgi phosphoprotein 3 (GOLPH3) has recently been implicated as an oncogene involved in the development of carcinoma in a number of organs. The expression of GOLPH3 in prostate cancer (PCa) tissues was investigated in the present study. Human PC‑3 and LNCaP PCa cell lines were analyzed in order to assess whether silencing of GOLPH3 expression affects cell vitality, migration and invasion, in vitro. An immunohistochemistry analysis was performed in order to measure the expression of GOLPH3 in samples from 117 patients with PCa and from 50 patients with benign prostatic hyperplasia (BPH). Associations between GOLPH3 expression and clinicopathological parameters, such as overall survival, were assessed. GOLPH3 expression was shown to be significantly greater in PCa tissues than in BPH tissues. GOLPH3 expression was positively correlated with Gleason score (P=0.031), tumor stage (T stage; P=0.020) and lymph node status (P=0.013), in patients with PCa. Biochemical recurrence‑free survival (serum prostate‑specific antigen‑based) and overall survival, were reduced in patients with GOLPH3‑positive PCa. A multivariate analysis indicated that GOLPH3 expression was an independent predictor of biochemical recurrence‑free survival [hazard ratio (HR), 2.943; 95% confidence interval (CI), 1.190‑5.521; P=0.028], and of overall survival (HR, 4.371; 95% CI, 2.045‑7.109; P=0.014). Transfection with GOLPH3‑targeted small interfering RNA reduced the capability of PC‑3 and LNCaP cell lines to proliferate, migrate and invade in vitro, compared with the controls. The level of GOLPH3 expression in radical prostatectomy samples may be useful for predicting biochemical recurrence‑free survival and overall survival in patients with PCa.

View Figures

View References

1	Denmeade SR and Isaacs JT: Development of prostate cancer treatment: the good news. Prostate. 58:211–224. 2004. View Article : Google Scholar : PubMed/NCBI
2	Sarkar D, Lebedeva IV, Su ZZ, et al: Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 67:5434–5442. 2007. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino P: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 167:528–534. 2002. View Article : Google Scholar : PubMed/NCBI
5	Patel AR and Stephenson AJ: Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol. 8:385–392. 2011. View Article : Google Scholar : PubMed/NCBI
6	Mishra MV, Champ CE, Den RB, Scher ED, Shen X, Trabulsi EJ, Lallas CD, Knudsen KE, Dicker AP and Showalter TN: Postprostatectomy radiation therapy: an evidence-based review. Future Oncol. 7:1429–1440. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chang AJ, Autio KA, Roach M III and Scher HI: High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 11:308–323. 2014. View Article : Google Scholar : PubMed/NCBI
8	Swanson GP and Basler JW: Prognostic factors for failure after prostatectomy. J Cancer. 2:1–19. 2010.
9	Crawford ED, Bennett CL, Andriole GL, Garnick MB and Petrylak DP: The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 112:548–560. 2013. View Article : Google Scholar : PubMed/NCBI
10	Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, et al: Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep. 26:1337–1342. 2011.PubMed/NCBI
12	Li XY, Liu W, Chen SF, Zhang LQ, Li XG and Wang LX: Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neurooncol. 105:159–163. 2011. View Article : Google Scholar : PubMed/NCBI
13	Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA and Sadar MD: Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics. 10:4762009. View Article : Google Scholar : PubMed/NCBI
14	Abraham RT: GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment Cell Melanoma Res. 22:378–379. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J and Song L: Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res. 18:4059–4069. 2012. View Article : Google Scholar : PubMed/NCBI
16	Steuber T, Erbersdobler A, Graefen M, Haese A, Huland H and Karakiewicz PI: Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy. Cancer. 106:775–782. 2006. View Article : Google Scholar : PubMed/NCBI
17	Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, Song LB and Song M: GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med. 10:1682012. View Article : Google Scholar : PubMed/NCBI
18	Zhou J, Xu T, Qin R, et al: Overexpression of Golgi phosphoprotein 3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol. 110:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L and Shen H: Increased expression of Golgi phosphoprotein 3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol. 7:1272012. View Article : Google Scholar
20	Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, et al: High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One. 7:e456222012. View Article : Google Scholar : PubMed/NCBI
21	Hu BS, Hu H, Zhu CY, Gu YL and Li JP: Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumor Biol. 34:515–520. 2013. View Article : Google Scholar